Stevanato Group S.p.A. (STVN)

NYQ – Real vaqt narxi. Valyuta: USD

17.84

-0.55 (-2.99%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

17.84

0.00 (0.00%)

Bozordan keyin: Jun 26, 2026, 5:05 PM EDT

11.06.2026

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes.

09.06.2026

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

The shares of both stocks are down so far this year. Stevanato is benefiting from the need for GLP-1 injectables.

08.06.2026

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- #DiabetesTherapies--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism.

03.06.2026

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders' Meeting”) held virtually on May 26, 2026, have passed. Details of the resolutions submitted to, and approved by, t.

03.06.2026

Implied Volatility Surging for Stevanato Stock Options

Investors need to pay close attention to STVN stock based on the movements in the options market lately.

12.05.2026

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

07.05.2026

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

08.06.2026

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

03.06.2026

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

07.05.2026

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026. First Quarter of 2026 Highlights (comparisons to prior-year period) For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions.

12.03.2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026. The Company will present on Tuesday, March 17, at 9.45-10.20 a.m. (ET). A live webcast will be available o.

Stevanato Group S.p.A. (STVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Stevanato Group S.p.A. (STVN)

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Implied Volatility Surging for Stevanato Stock Options

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Implied Volatility Surging for Stevanato Stock Options

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Search stocks

Stevanato Group S.p.A. (STVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Stevanato Group S.p.A. (STVN)

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Implied Volatility Surging for Stevanato Stock Options

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum

Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside

2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Implied Volatility Surging for Stevanato Stock Options

Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript

Videolar

No Data

Press-relizlar

Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum